TAAV Manufacturing Solutions

TAAV is a Spain-based gene therapy manufacturing company focused on enzymatic DNA used as starting material for recombinant adeno-associated virus (rAAV) production. The company operates as a fee-for-service CDMO and manufactures neDNA, a synthetic linear double-stranded closed-ended DNA alternative to plasmid DNA for research, preclinical, clinical, and commercial AAV programs. TAAV was originally formed as a joint venture in the enzymatic DNA and AAV manufacturing space and became fully owned by AskBio in 2022, making it part of the Bayer group through AskBio. Its offering is positioned to shorten manufacturing timelines, improve yields at small scale, and avoid bacterial backbone sequences associated with conventional plasmid production. The company serves biopharma companies, research centers, and other developers of rAAV-based gene therapies from its San Sebastian, Spain facility.